| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
| Targets |
Non-ionic detergent; surfactant
|
|---|---|
| ln Vitro |
Adsorption of a typical sugar-based surfactant,n-dodecyl-β-d-maltoside (DM), on hydrophilic solids, silica, alumina, titania, and hematite, and a hydrophobic solid, graphite, was studied. Effects of salts and pH on the adsorption on alumina as well as the electrokinetic potential of the particles after surfactant adsorption were studied to determine the adsorption mechanisms. Hydrophobicity and settling rate were measured to explore the surfactant conformation on the particle surfaces. For hydrophilic solids, DM was found to adsorb strongly on alumina, titania, and hematite but weakly on silica. While hydrogen bonding is postulated to be the major driving force for the adsorption on hydrophilic solids, for hydrophobic solid, the adsorption is mainly due to the hydrophobic interactions. The different behaviors of surfactant on hydrophilic and hydrophobic solids were attributed to the different interactions between surfactant and solids. Also, the surfactant is estimated to form a bilayer on alumina while on graphite it forms a monolayer. The surface hydrophobicity and stability of the solids are discussed in terms of the adsorbed monolayer/bilayer formation on the particles[1].
|
| References |
[1]. Adsorption ofn-Dodecyl-β-d-maltoside on Solids[J].J Colloid Interface, 1997, 256(1):202-208.
[2]. Evidence of Increased Hydrophobicity and Dynamics inside the Tail Region of Glycolipid Self-Assemblies Using 2- n-Alkyl-Pyrene Derivatives to Probe Different Locations. Langmuir . 2019 Jul 23;35(29):9584-9592. |
| Additional Infomation |
Dodecyl beta-D-maltoside is a glycoside resulting from attachment of a dodecyl group to the reducing-end anomeric centre of a beta-maltose molecule. It has a role as a detergent. It is a glycoside and a disaccharide derivative. It derives from a hydride of a beta-maltose.
Dodecyl Maltoside is an alkyl disaccharide compound and polar surfactant, with potential adenoviral transduction-enhancing activity. Upon administration as a bladder wash, dodecyl maltoside (DDM) acts as a surfactant and enhances adenoviral transduction and infection of the bladder urothelium. This may allow for an efficient delivery of oncolytic viruses in the treatment of bladder cancer. |
| Molecular Formula |
C24H46O11
|
|---|---|
| Molecular Weight |
510.6154
|
| Exact Mass |
510.304
|
| Elemental Analysis |
C, 56.45; H, 9.08; O, 34.47
|
| CAS # |
69227-93-6
|
| PubChem CID |
114880
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
703.5±60.0 °C at 760 mmHg
|
| Melting Point |
224-226 °C(lit.)
|
| Flash Point |
379.3±32.9 °C
|
| Vapour Pressure |
0.0±5.1 mmHg at 25°C
|
| Index of Refraction |
1.552
|
| LogP |
2.69
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
35
|
| Complexity |
554
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
O([C@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])O[H])O[H])[C@]1([H])[C@@]([H])(C([H])([H])O[H])O[C@]([H])([C@@]([H])([C@@]1([H])O[H])O[H])OC([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H]
|
| InChi Key |
NLEBIOOXCVAHBD-QKMCSOCLSA-N
|
| InChi Code |
InChI=1S/C24H46O11/c1-2-3-4-5-6-7-8-9-10-11-12-32-23-21(31)19(29)22(16(14-26)34-23)35-24-20(30)18(28)17(27)15(13-25)33-24/h15-31H,2-14H2,1H3/t15-,16-,17-,18+,19-,20-,21-,22-,23-,24-/m1/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-6-dodecoxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| Synonyms |
69227-93-6; n-DODECYL-beta-D-MALTOSIDE; Dodecyl maltoside; Lauryl maltoside; Dodecyl-beta-D-maltoside; N-Dodecyl b-D-maltoside; n-Dodecyl beta-D-maltoside; n-Dodecyl ;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~195.84 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (195.84 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9584 mL | 9.7920 mL | 19.5840 mL | |
| 5 mM | 0.3917 mL | 1.9584 mL | 3.9168 mL | |
| 10 mM | 0.1958 mL | 0.9792 mL | 1.9584 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06443944 | AVAILABLE | Bladder Cancer Non-Muscle Invasive Bladder Cancer Urologic Cancer Urothelial Carcinoma |
CG Oncology, Inc. | Drug: Cretostimogene Grenadenorepvec
Other: n-dodecyl-B-D-maltoside |
||
| NCT06111235 | RECRUITING | Drug: Cretostimogene Grenadenorepvec
Other: n-dodecyl-B-D-maltoside |
Bladder Cancer Non Muscle Invasive Bladder Cancer Urologic Cancer Urothelial Carcinoma |
CG Oncology, Inc. | 2023-12-14 | Phase 3 |
| NCT04452591 | RECRUITING | Biological: Cretostimogene Grenadenorepvec
Other: n-dodecyl-B-D-maltoside |
High-grade Ta/ T1 Papillary Disease Bladder Cancer Non Muscle Invasive Bladder Cancer |
CG Oncology, Inc. | 2020-10-27 | Phase 3 |
| NCT04387461 | UNKNOWN STATUS | Biological: CG0070 Biological: Pembrolizumab Injection Other: n-dodecyl-B-D-maltoside |
Non Muscle Invasive Bladder Cancer | CG Oncology, Inc. | 2020-12-08 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA